跳至主要内容
临床试验/NCT01356108
NCT01356108已完成不适用

Implantation of the SAPIEN™ Transcatheter Heart Valve (THV) in the Pulmonic Position

Edwards Lifesciences16 个研究点 分布在 9 个国家目标入组 127 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
127
试验地点
16
主要终点
Safety

研究概览

简要总结

The purpose of this registry is to retrospectively and prospectively obtain clinical data in consecutively treated patients, in order to demonstrate that the commercially available Edwards SAPIEN Valve with the RF3 delivery system is a safe and effective treatment for patients with pulmonary regurgitation or stenosis.

详细描述

Consecutive patient data should be collected at discharge, 6 months, 12 months and 2-5 years post-implant.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Symptomatic with a regurgitant or stenotic pulmonary valved conduit.

排除标准

  • Angiographic evidence of coronary artery compression.
  • RV-PA pulmonary conduit size that is either too large or too small to accommodate the SAPIEN THV.
  • Thrombus or intracardiac mass in the right atrium, right ventricle, and/or pulmonic valve.
  • Severe coagulation problems and/or unable to tolerate anticoagulation/antiplatelet therapy.
  • Active bacterial endocarditis or other active infections.
  • Illeofemoral venous stenosis that may prevent the placement of the introducer sheath and/or central venous vascular tortuosities that may prevent advancement of the delivery system to the heart or into the pulmonary artery.
  • Presence of any prosthetic valve in the tricuspid position.
  • Unstable coronary artery disease-related angina.
  • Placement of the SAPIEN THV in pregnant females.

结局指标

主要结局

Safety

时间窗: 6 months

Procedure/Device Success and Freedom from device or procedure related death

次要结局

  • Safety and Effectiveness(6 Months)

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验